📡 TrialPulse
RECRUITINGPHASE1 / PHASE2

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

NCT07619521·National Cancer Institute (NCI)·source: ClinicalTrials.gov ↗·updated 2026-10-19
← All trials
Registry history
Events detected for this trial — severity × confidence × recency
Neon
How to read the confidence score: 1.0 = observed — the registry record itself changed (a fact). <1.0 (e.g. 0.7) = signal — inferred by a heuristic rule from the data; it flags something worth a look, it is not a confirmed finding. Values below are shown raw from the database; the highlighted parts are the actual values, dimmed parts are JSON syntax.
trial seenhigh2026-10-19
null → {"status":"RECRUITING","last_update_posted_at":"2026-10-19"}
Key dates
Start2027-06-01
Primary completion2028-09-08
Enrollment31estimated
Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal AdenocarcinomaBIOLOGICALDRUGPROCEDURE
Site map
Per-site markers colored by site status
Live map
recruitingYale University Cancer Center LAONew Haven, United States
recruitingUPMC Hillman Cancer CenterPittsburgh, United States